An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Abstract Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). Methods Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equiva...

Full description

Bibliographic Details
Main Authors: Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Arthritis Research & Therapy
Subjects:
ABP 501
Adalimumab
Rheumatoid arthritis
Long-term safety
Efficacy
Biosimilar
Online Access:http://link.springer.com/article/10.1186/s13075-019-1857-3

Internet

http://link.springer.com/article/10.1186/s13075-019-1857-3

Similar Items